Short Interest in Talphera, Inc. (NASDAQ:TLPH) Drops By 49.0%

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 30,500 shares, a decline of 49.0% from the December 31st total of 59,800 shares. Based on an average daily volume of 111,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s stock are short sold.

Talphera Price Performance

Shares of TLPH stock traded down $0.03 during trading hours on Wednesday, reaching $0.70. 35,141 shares of the company’s stock were exchanged, compared to its average volume of 101,124. The company’s 50 day moving average is $0.65 and its two-hundred day moving average is $0.81. The company has a market cap of $11.94 million, a P/E ratio of -1.02 and a beta of 0.28. Talphera has a 1 year low of $0.50 and a 1 year high of $1.61.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on TLPH shares. Rodman & Renshaw began coverage on Talphera in a research report on Tuesday. They set a “buy” rating and a $4.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Talphera in a research note on Tuesday, January 21st. Maxim Group raised shares of Talphera to a “strong-buy” rating in a report on Friday, November 8th. Finally, RODMAN&RENSHAW raised Talphera to a “strong-buy” rating in a report on Tuesday.

Institutional Trading of Talphera

An institutional investor recently bought a new position in Talphera stock. Rosalind Advisors Inc. acquired a new position in Talphera, Inc. (NASDAQ:TLPH) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera makes up about 0.4% of Rosalind Advisors Inc.’s holdings, making the stock its 25th largest holding. Rosalind Advisors Inc. owned about 4.47% of Talphera as of its most recent SEC filing. 37.67% of the stock is owned by institutional investors and hedge funds.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.